8-K: Moderna Q2 2026 Results: Revenue Flat, Net Loss Narrows

Moderna reported Q2 2026 results with flat revenue of $145 million, a GAAP net loss of $0.8 billion, and improved operating expense outlook for the year.

Summary

• Moderna reported second quarter 2026 revenue of $145 million, a slight increase from $142 million in the prior year's second quarter.
• The company reported a GAAP net loss of $0.8 billion for Q2 2026, an improvement of $43 million compared to Q2 2025.
• GAAP loss per share was $(1.97) in Q2 2026, compared to $(2.13) in Q2 2025.
• Research and development expenses decreased by 7% to $651 million, and selling, general, and administrative expenses decreased by 6% to $216 million.
• The company reiterated its plan to deliver up to 10% revenue growth in 2026.
• Moderna improved its 2026 GAAP operating expense outlook by approximately $0.2 billion and expects its year-end cash balance to be between $4.7 billion and $5.2 billion.
• The company anticipates a potential approval for its seasonal influenza vaccine candidate, mFLUSIVA, with an August 5th PDUFA date.
• Moderna's norovirus vaccine candidate, mRNA-1403, did not meet statistical criteria for early success in its Phase 3 interim analysis.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive report. While revenue is flat and a net loss persists, the improved expense outlook, strengthened cash position, and progress in pipeline development, including potential near-term approvals, are positive indicators. However, the setback with the norovirus vaccine and the delay in the flu/COVID combo vaccine submission temper the overall sentiment.

Positives

• Revenue increased slightly to $145 million in Q2 2026 from $142 million in Q2 2025.
• GAAP net loss improved by 5% to $(0.8) billion in Q2 2026 compared to Q2 2025.
• GAAP loss per share improved to $(1.97) in Q2 2026 from $(2.13) in Q2 2025.
• Operating expenses were reduced, with R&D expenses down 7% and SG&A expenses down 6% year-over-year.
• The 2026 GAAP operating expense outlook was improved by approximately $0.2 billion.
• The projected 2026 year-end cash balance was improved to $4.7 $5.2 billion.
• Received regulatory approvals for mRESVIA in Australia and Mexico, and mNEXSPIKE in Japan and Taiwan.
• mFLUSIVA, the seasonal influenza vaccine candidate, received a unanimous recommendation from the VRBPAC.

Negatives

• Reported a GAAP net loss of $(0.8) billion for the second quarter of 2026.
• Total revenue for the second quarter of 2026 was $145 million, indicating flat growth compared to the prior year.
• Cost of sales included $41 million in inventory write-downs and $23 million in unutilized manufacturing capacity costs.
• mRNA-1403, the norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3 interim analysis.
• Cash, cash equivalents and investments decreased from $7.5 billion as of March 31, 2026, to $6.9 billion as of June 30, 2026.
• The company paid $950 million in July 2026 related to a litigation settlement.

Risks

• The forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied.
• These risks include those described in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent SEC filings.
• mRNA-1403, the norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3 interim analysis, and the company is preparing to enroll an additional cohort.
• The company is awaiting further guidance from the U.S. FDA on refiling the submission for its flu plus COVID combination vaccine (mRNA-1083).

Future Outlook

Moderna targets up to 10% revenue growth in 2026, with approximately 55% of second-half revenue expected in the third quarter. The company has improved its 2026 GAAP operating expense outlook by $0.2 billion and projects a year-end cash balance of $4.7 to $5.2 billion. Anticipates potential approval of mFLUSIVA by August 5, 2026, and expects potential Phase 3 adjuvant melanoma data in 2026 for mRNA-4157. Potential data for the propionic acidemia therapeutic (mRNA-3927) is also expected in 2026.

Management Comments

• "The second quarter marked another period of strong execution for Moderna as we advanced our pipeline and strengthened our financial profile with an improved 2026 operating expense outlook," said Stphane Bancel, Chief Executive Officer of Moderna.
• "In the second half of 2026, we are preparing for the potential approval of mFLUSIVA in the U.S., which would be our fifth approved product, and continue to anticipate important pivotal readouts for our intismeran in melanoma and propionic acidemia programs."

Industry Context

StockSavvy.ai notes that Moderna's Q2 2026 results reflect the ongoing transition in the vaccine market post-pandemic, with a focus shifting towards next-generation combination vaccines and therapeutics for oncology and rare diseases. The improved operating expense outlook and strengthened cash position are positive signs of financial discipline amidst pipeline development.

Comparison to Industry Standards

• Moderna's revenue of $145 million in Q2 2026 shows flat year-over-year growth, which is below the high-growth rates seen in the peak COVID-19 vaccine sales period. Many biopharmaceutical companies are experiencing revenue normalization post-pandemic.
• The net loss of $(0.8) billion is substantial, but the improvement from the prior year is a positive trend. Companies heavily invested in R&D, like Moderna, often report losses during development phases.
• The company's cash position of $6.9 billion remains strong, providing significant runway for continued research and development, which is crucial for innovation in the biopharmaceutical sector.
• The focus on a diversified pipeline including influenza, oncology (mRNA-4157 with Merck), and rare diseases aligns with industry trends of expanding mRNA applications beyond infectious diseases.

Management Changes

Legal Proceedings

• Moderna paid $950 million in July 2026 related to a litigation settlement announced in the first quarter of 2026.

Stakeholder Impact

• Shareholders: The flat revenue and continued net loss may be a concern, but the improved expense outlook and strengthened cash position offer some reassurance. Potential approvals of new products could drive future value.
• Employees: Continued investment in R&D and pipeline advancement suggests ongoing opportunities and job security within the company.
• Partners (e.g., Merck): Progress in collaborative programs like mRNA-4157 is positive for partners involved in advancing these therapies.
• Creditors: The strong cash position and improved year-end cash projections suggest continued ability to meet financial obligations.

Next Steps

• Awaiting potential approval of mFLUSIVA with an August 5th PDUFA date.
• Preparing to enroll an additional cohort for mRNA-1403 (norovirus vaccine candidate).
• Awaiting further guidance from the U.S. FDA on refiling the submission for mRNA-1083 (flu plus COVID combination vaccine).
• Expecting potential Phase 3 adjuvant melanoma data in 2026 for mRNA-4157.
• Expecting potential data in 2026 for the propionic acidemia (PA) therapeutic (mRNA-3927).
• Hosting Investor and Analyst Day on November 12, 2026.

Key Dates

Recommendation

The filing presents a mixed picture. While Moderna shows financial discipline with improved expense outlooks and a strong cash position, revenue remains flat, and a significant net loss continues. The setback with the norovirus vaccine and regulatory delays for the flu/COVID combo vaccine are notable negatives. However, the potential approval of mFLUSIVA and ongoing progress in oncology and rare disease programs offer future growth prospects. A 'hold' recommendation reflects the balance between current challenges and future potential.

Keywords

mRNA, vaccine, influenza, COVID, oncology, rare disease, clinical trials, financial results